Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Alessio CortelliniMarcello TiseoGiuseppe L BannaFederico CappuzzoJoachim G J V AertsFausto BarbieriRaffaele GiustiEmilio BriaDiego CortinovisFrancesco GrossiMaria R MigliorinoDomenico GalettaFrancesco PassigliaDaniele SantiniRossana BerardiAlessandro MorabitoCarlo GenovaFrancesca MazzoniVincenzo Di NoiaDiego SignorelliAlessandro TuziAlain GelibterPaolo MarchettiMarianna MacerelliFrancesca RastelliRita ChiariDanilo RoccoStefania GoriMichele De TursiGiovanni MansuetoFederica ZorattoMatteo SantoniMarianna TudiniErika RijavecMarco FilettiAnnamaria CatinoPamela PizzutiloLuca SalaFabrizio CitarellaRussano MarcoMariangela TorniaiLuca CantiniGiada TargatoVincenzo SforzaOlga NigroMiriam G FerraraEttore D'ArgentoSebastiano ButiPaola BordiLorenzo AntonuzzoSimona ScodesLorenza LandiGiorgia GuaitoliCinzia BaldessariLuigi Della GravaraMaria Giovanna Dal BelloRobert A BelderbosPaolo BironzoSimona CarnioSerena RicciardiAlessio GriecoAlessandro De TomaClaudia ProtoAlex FriedlaenderOrnella CantaleBiagio RicciutiAlfredo AddeoGiulio MetroCorrado FicorellaGiampiero PorzioPublished in: Cancer immunology, immunotherapy : CII (2020)
Pembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials. Questions regarding the effectiveness in clinical subgroups, such as patients with poorer PS and with liver/bone metastases, still remain to be addressed. We confirmed that the absence of tobacco exposure, and the presence of bone and liver metastasis are associated with worse clinical outcomes to pembrolizumab. Increasing levels of PD-L1 expression may help identifying a subset of patients who derive a greater benefit from pembrolizumab monotherapy.